Proactive pharmaceutical care interventions decrease patients' nonadherence to osteoporosis medication

Osteoporosis International

Volumn 25, Issue 6, 2014, Pages 1807-1812

  Stuurman Bieze, A G G ^a,b   Hiddink, E G ^b,c,d   Van Boven, J F M ^c   Vegter, S ^c  

^a West Pharmacy ^*  (Netherlands)

^b Stichting Health Base   (Netherlands)

^c UNIVERSITY OF GRONINGEN   (Netherlands)

^d PharmaPartners   (Netherlands)

Author keywords

Adherence; Bisphosphonates; Osteoporosis; Persistence; Pharmaceutical care; Pharmacist intervention

Indexed keywords

BISPHOSPHONIC ACID DERIVATIVE; CORTICOSTEROID; BONE DENSITY CONSERVATION AGENT;

AGED; ARTICLE; CORTICOSTEROID THERAPY; FEMALE; FOLLOW UP; HUMAN; INTERVENTION STUDY; MAJOR CLINICAL STUDY; MALE; OSTEOPOROSIS; OUTCOME ASSESSMENT; PATIENT COMPLIANCE; PATIENT COUNSELING; PATIENT SATISFACTION; PHARMACEUTICAL CARE; PHARMACIST; PHARMACY; PRIORITY JOURNAL; PROSPECTIVE STUDY; TREATMENT REFUSAL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; COUNSELING; DRUG MONITORING; EPIDEMIOLOGY; HEALTH PERSONNEL ATTITUDE; MEDICATION COMPLIANCE; MEDICATION THERAPY MANAGEMENT; MIDDLE AGED; MULTICENTER STUDY; NETHERLANDS; ORGANIZATION AND MANAGEMENT; PATIENT DROPOUTS; PROCEDURES; PROGRAM EVALUATION; PSYCHOLOGY; STATISTICS AND NUMERICAL DATA; VERY ELDERLY;

AGED; AGED, 80 AND OVER; ATTITUDE OF HEALTH PERSONNEL; BONE DENSITY CONSERVATION AGENTS; COMMUNITY PHARMACY SERVICES; COUNSELING; DRUG MONITORING; FEMALE; FOLLOW-UP STUDIES; HISTORICALLY CONTROLLED STUDY; HUMANS; MALE; MEDICATION ADHERENCE; MEDICATION THERAPY MANAGEMENT; MIDDLE AGED; NETHERLANDS; OSTEOPOROSIS; PATIENT DROPOUTS; PATIENT SATISFACTION; PHARMACISTS; PROGRAM EVALUATION;

EID: 84901857680     PISSN: 0937941X     EISSN: 14332965     Source Type: Journal    
DOI: 10.1007/s00198-014-2659-8     Document Type: Article

References (22)

1. Lips P, van Schoor NM (2005) Quality of life in patients with osteoporosis. Osteoporos Int 16(5):447-455
2. Freemantle N, Cooper C, Diez-Perez A, Gitlin M, Radcliffe H, Shepherd S, Roux C (2013) Results of indirect and mixed treatment comparison of fracture efficacy for osteoporosis treatments: a meta-analysis. Osteoporos Int 24(1):209-217
3. van Boven JF, de Boer PT, Postma MJ, Vegter S (2013) Persistence with osteoporosis medication among newly-treated osteoporotic patients. J Bone Miner Metab 31(5):562-570
4. Netelenbos JC, Geusens PP, Ypma G, Buijs SJ (2011) Adherence and profile of non-persistence in patients treated for osteoporosis - a large-scale, long-term retrospective study in The Netherlands. Osteoporos Int 22(5):1537-1546
5. Imaz I, Zegarra P, Gonzalez-Enriquez J, Rubio B, Alcazar R, Amate JM (2010) Poor bisphosphonate adherence for treatment of osteoporosis increases fracture risk: systematic review and meta-analysis. Osteoporos Int 21(11):1943-1951
6. Landfeldt E, Lundkvist J, Strom O (2011) The societal burden of poor persistence to treatment of osteoporosis in Sweden. Bone 48(2):380-388
7. Hiligsmann M, Rabenda V, Bruyere O, Reginster JY (2010) The clinical and economic burden of non-adherence with oral bisphosphonates in osteoporotic patients. Health Policy 96(2):170-177
8. Hiligsmann M, Rabenda V, Gathon HJ, Ethgen O, Reginster JY (2010) Potential clinical and economic impact of nonadherence with osteoporosis medications. Calcif Tissue Int 86(3):202-210
9. Elias MN, Burden AM, Cadarette SM (2011) The impact of pharmacist interventions on osteoporosis management: a systematic review. Osteoporos Int 22(10):2587-2596
10. Stuurman-Bieze AG, Hiddink EG, van Boven JF, Vegter S (2013) Proactive pharmaceutical care interventions improve patients' adherence to lipid-lowering medication. Ann Pharmacother 47(11):1448-1456
11. Vegter S, Oosterhof P, Van Boven JF, Stuurman-Bieze AG, Hiddink EG, Postma MJ (2014) Improving adherence to lipid-lowering therapy in a community pharmacy intervention program: a cost-effectiveness analysis. J Manag Care Pharm in press
12. Yeaw J, Benner JS, Walt JG, Sian S, Smith DB (2009) Comparing adherence and persistence across 6 chronic medication classes. J Manag Care Pharm 15(9):728-740
13. Visser ST, Schuiling-Veninga CC, Bos JH, de Jong-van den Berg LT, Postma MJ (2013) The population-based prescription database IADB.nl: its development, usefulness in outcomes research and challenges. Exp Rev Pharmacoecon Outcome Res 13(3):285-292
14. Vegter S, Nguyen NH, Visser ST, de Jong-van den Berg LT, Postma MJ, Boersma C (2011) Compliance, persistence, and switching patterns for ACE inhibitors and ARBs. Am J Manag Care 17(9):609-616
15. Stuurman-Bieze AG, Hiddink EG (2010) Apotheekteam verbetert therapietrouw osteoporosemedicatie door gestructureerde medicatiebegeleiding en geautomatiseerde opsporing van suboptimale farmacotherapie. PW Wetenschappelijk Platf 4(7/8):128-135 [article in Dutch]
16. McDonough RP, Doucette WR, Kumbera P, Klepser DG (2005) An evaluation of managing and educating patients on the risk of glucocorticoid-induced osteoporosis. Value Health 8(1):24-31
17. Crockett JA, Taylor SJ, McLeod LJ (2008) Patient responses to an integrated service, initiated by community pharmacists, for the prevention of osteoporosis. Int J Pharm Pract 16:65-72
18. Yuksel N, Majumdar SR, Biggs C, Tsuyuki RT (2010) Community pharmacist-initiated screening program for osteoporosis: randomized controlled trial. Osteoporos Int 21(3):391-398
19. Lai PS, Chua SS, Chew YY, Chan SP (2011) Effects of pharmaceutical care on adherence and persistence to bisphosphonates in postmenopausal osteoporotic women. J Clin Pharm Ther 36(5):557-567
20. Gleeson T, Iversen MD, Avorn J, Brookhart AM, Katz JN, Losina E, May F, Patrick AR, Shrank WH, Solomon DH (2009) Interventions to improve adherence and persistence with osteoporosis medications: a systematic literature review. Osteoporos Int 20(12):2127-2134
21. Cooper A, Drake J, Brankin E (2006) PERSIST investigators: treatment persistence with once-monthly ibandronate and patient support vs. once-weekly alendronate: results from the PERSIST study. Int J Clin Pract 60(8):896-905
22. Elders PJM, Dinant GJ, Van Geel T, Maartens LWF, Merlijn T, Geijer RMM, Geraets JJXR (2012) NHG-Standaard Fractuurpreventie (tweede herziening). Huisarts Wet 55:452-458